Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACONW NASDAQ:ATNFW NASDAQ:SCLXW NASDAQ:SXTPW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONWAclarion$0.04+12.4%$0.03$0.01▼$0.24N/AN/A31,639 shs665 shsATNFW180 Life Sciences$0.24+3.5%$0.09$0.00▼$0.62N/AN/A501,334 shs270,934 shsSCLXWScilex$0.46-3.1%$0.34$0.04▼$0.65N/AN/A10,777 shs7,614 shsSXTPW60 Degrees Pharmaceuticals$0.09-3.6%$0.07$0.01▼$0.16N/AN/A13,897 shs310 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONWAclarion+3.42%-26.37%+23.05%+20.60%-6.68%ATNFW180 Life Sciences-11.25%-14.19%+1,661.37%+2,784.25%+2,713.90%SCLXWScilex0.00%-1.10%-12.09%+410.43%+37.16%SXTPW60 Degrees Pharmaceuticals+0.11%-14.49%+91.82%+52.70%+56.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACONWAclarionN/AN/AN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ASCLXWScilexN/AN/AN/AN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACONWAclarion 0.00N/AN/AN/AATNFW180 Life Sciences 0.00N/AN/AN/ASCLXWScilex 0.00N/AN/AN/ASXTPW60 Degrees Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACONWAclarion$62.95KN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/ASCLXWScilex$44.24MN/AN/AN/AN/AN/ASXTPW60 Degrees Pharmaceuticals$641.41KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACONWAclarionN/AN/A0.00∞N/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ASCLXWScilexN/AN/A0.00∞N/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACONWAclarionN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/ASCLXWScilexN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACONWAclarionN/AATNFW180 Life SciencesN/ASCLXWScilexN/ASXTPW60 Degrees PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACONWAclarionN/AATNFW180 Life SciencesN/ASCLXWScilexN/ASXTPW60 Degrees PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACONWAclarion7N/AN/ANot OptionableATNFW180 Life Sciences7N/AN/ANot OptionableSCLXWScilex105N/AN/ANot OptionableSXTPW60 Degrees Pharmaceuticals2N/AN/ANot OptionableSCLXW, ATNFW, SXTPW, and ACONW HeadlinesRecent News About These Companies60 Degrees Pharmaceuticals Initiates Phase II Clinical Trial of Tafenoquine for Chronic Babesiosis TreatmentAugust 19, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Reports Q2 2025 EarningsAugust 13, 2025 | tipranks.com60 Degrees Pharmaceuticals Inc (SXTP) - Investing.com UKJuly 23, 2025 | uk.investing.com60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella BacteriaJuly 19, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Secures $5M in Recent OfferingJuly 18, 2025 | tipranks.com60 Degrees Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and WarrantsJuly 15, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Inc (SXTP) - Investing.comJune 30, 2025 | investing.com60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVJune 6, 2025 | usatoday.com60 Degrees Pharmaceuticals Introduces New 8-Count Bottle for ARAKODA® Malaria ProphylaxisJune 6, 2025 | nasdaq.com60 Degrees introduces eight-count bottle format for ARAKODAJune 4, 2025 | msn.com60 Degrees announces results from an insurance claims analysis on babesiosisJune 4, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Highlights Major Discrepancies in Babesiosis Diagnosis Estimates in U.S.April 24, 2025 | nasdaq.com60 Degrees Pharmaceuticals signs Patient License Agreement with YaleApril 8, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals Announces 2024 Annual ResultsMarch 28, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Inc trading halted, news pendingFebruary 21, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals files to sell 3.74M shares of common stock for holderFebruary 14, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals announces stock and warrant saleJanuary 29, 2025 | msn.comThe Market’s Eyeing 60 Degrees Pharmaceuticals (SXTP): Will the Surge Last?January 29, 2025 | bovnews.comBMedia Sentiment Over TimeSCLXW, ATNFW, SXTPW, and ACONW Company DescriptionsAclarion NASDAQ:ACONW$0.04 +0.00 (+12.40%) As of 02:50 PM EasternAclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.180 Life Sciences NASDAQ:ATNFW$0.24 +0.01 (+3.51%) As of 08/28/2025180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Scilex NASDAQ:SCLXW$0.46 -0.01 (-3.10%) As of 02:49 PM EasternScilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.60 Degrees Pharmaceuticals NASDAQ:SXTPW$0.09 0.00 (-3.62%) As of 11:22 AM Eastern60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access